Pay in 4 interest-free payments of $7.42 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
CT-388 and CT-868, developed by Carmot Therapeutics, are GIPR/GLP-1R agonists under investigation in obese patients, including those with type 1 diabetes (NCT04838405, NCT06062069)
These weight loss medications have been shown to help in blood sugar control in patients with type 2 diabetes as helps in regulating insulin production and glucose metabolism in the body
In the matched non-nave cohorts with baseline and follow-up weight data, tirzepatide initiators had a mean percent weight reduction of 7.1% while semaglutide initiators had a mean percent reduction of 3.3%
Not because the drug does something extra, but because 50 pounds takes more load off a skeleton than five
US$ 23.22
US$ 21.20
US$ 25.04
US$ 23.43
US$ 24.78
